Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FTC Claims Revived Over Teva-AbbVie 'Pay For Delay' Deal

AndroGel $448M Pay-For-Delay Disgorgement Spiked On Appeal

Oct 02 2020

• By Brenda Sandburg

Court of appeals building portico in Washington DC — Third Circuit issues mixed ruling in FTC's Androgel pay-for-delay suit • Source: Shutterstock

Related Content

Teva Barred From Agreeing ‘No-Authorized Generics’ Deals Under Reverse-Payment FTC Settlement

Feb 20 2019

FTC Rules Impax $112mn Pay-For-Delay Deal With Endo Was Illegal

Apr 02 2019

Court stings AbbVie with an AndroGel fine

Jul 06 2018

Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits

Jun 24 2013

FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal

Jul 02 2018

Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

Feb 21 2019

Related Companies

AbbVie Inc.

Teva Pharmaceuticals USA Inc.

Perrigo Company PLC

Impax Laboratories, Inc.

Additional Topics

United States Legal Issues Policy Intellectual Property Deals Generic Drugs BioPharmaceutical

More from Legal & IP

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window